GlassScriptPhysician profile
Robin S Lucas
NPI 1841286697
$16,457.82
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $214 · 2021: $579 · 2022: $1,154 · 2023: $7,074 · 2024: $6,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,900 · Food and Beverage: $3,279 · Travel and Lodging: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,900.00 |
| Food and Beverage | $3,278.82 |
| Travel and Lodging | $675.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $12,677.09 | 2019-2024 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,160.35 | 2020-2024 | Nucala, Trelegy Ellipta |
| Mylan Specialty L.P. | $623.59 | 2019-2024 | Yupelri |
| Novo Nordisk INC | $284.60 | 2020-2024 | Ozempic, Rybelsus |
| Philips North America LLC | $257.45 | 2019-2023 | |
| Genentech USA, INC. | $239.34 | 2019-2024 | Xolair |
| United Therapeutics Corporation | $150.70 | 2021-2023 | Tyvaso |
| Genzyme Corporation | $149.81 | 2019-2024 | |
| Amgen INC. | $98.36 | 2022-2023 | Tezspire |
| Sunovion Pharmaceuticals INC. | $85.29 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.21 | 2019-2023 | |
| Ani Pharmaceuticals, INC. | $80.44 | 2022-2023 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $80.25 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $73.56 | 2019-2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.49 | 2022-2023 | Ofev |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $59.89 | 2022-2023 | |
| Grifols USA, LLC | $49.78 | 2020-2023 | Prolastin-C Liquid |
| Abbott Laboratories | $47.70 | 2021-2023 | Freestyle Libre 3 |
| Mallinckrodt Hospital Products INC. | $41.16 | 2020-2023 | Acthar |
| Merck Sharp & Dohme LLC | $33.97 | 2023-2024 | Winrevair |
| Lilly USA, LLC | $29.67 | 2020-2024 | Jardiance |
| Amarin Pharma, INC. | $26.99 | 2020-2021 | |
| Dentsply Sirona INC | $14.63 | 2024 | Prime&Bond Nt Nano-Technology Light Cured Dental Adhesive |
| Janssen Pharmaceuticals, INC | $14.47 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.30 | 2019 | |
| Gilead Sciences, INC. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Lucas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.